However, it is still not well understood how alterations in the expression of FADD and IAPs affect death pathway signaling and contribute to resistance to therapies targeting the death pathways in cancers, especially in HNSCC differing in HPV status. This evidence concerns the gene FADD and head and neck squamous cell carcinoma.